NEW YORK – Namocell said on Monday that it has signed an agreement with SingLab Technologies to distribute its single-cell isolation systems in Singapore.
The Mountain View, California-based company provides single-cell sorting and dispensing platforms for research and therapeutics development.
"Advances in cell biology have created a new era of cell-based research and therapeutics," said SingLab CEO Michael Choi in a statement. "[Namocell's] benchtop low-pressure single-cell dispensers are designed to protect the viability and integrity of isolated cells for a wide range of downstream applications."
"There has been increasing demand for our single-cell dispenser systems in the Southeast Asia market," Junyu Lin, CEO of Namocell, said in a statement. "[SingLab's] strong technical expertise in cell-based R&D products and excellent customer service capabilities make them a great partner."
Financial terms of the agreement were not disclosed.
In March, Namocell signed an agreement with Germany-based Omni Life Science (OLS) to distribute the firm's single-cell dispensers in Germany and Austria.